Cargando…

Mechanism of PARP inhibitor resistance and potential overcoming strategies

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Xiaoyu, Li, Ping, Zhou, Qi, He, Ruyuan, Wang, Guannan, Zhu, Shiya, Bagheri, Amir, Kupfer, Gary, Pei, Huadong, Li, Juanjuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/ https://www.ncbi.nlm.nih.gov/pubmed/37588193 http://dx.doi.org/10.1016/j.gendis.2023.02.014

Ejemplares similares

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
por: Prados-Carvajal, Rosario, et al.
Publicado: (2021)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
por: Fu, Xiaoyu, et al.
Publicado: (2022)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016)

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance
por: Kyo, Satoru, et al.
Publicado: (2022)

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
por: Kim, Dongha, et al.
Publicado: (2022)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
por: Zhang, Xudong, et al.
Publicado: (2023)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
por: Veneziani, Ana C., et al.
Publicado: (2023)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Strategies to overcome drug resistance using SHP2 inhibitors
por: Liu, Meng, et al.
Publicado: (2021)

PARP inhibitor resistance: the underlying mechanisms and clinical implications
por: Li, He, et al.
Publicado: (2020)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells
por: Liu, Hanyu, et al.
Publicado: (2016)

Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance
por: Lovsund, Taylor, et al.
Publicado: (2023)

Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer
por: Brodie, Seth A., et al.
Publicado: (2015)

Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor
por: Xu, Yurui, et al.
Publicado: (2017)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
por: Serra, Violeta, et al.
Publicado: (2022)

Role of Akt Activation in PARP Inhibitor Resistance in Cancer
por: Gallyas, Ferenc, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c93esqnchcb2jbsiu2ga9vbngo